Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Prexton Therapeutics
Biotech
Lundbeck to buy Prexton for phase 2 Parkinson’s drug
The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.
Nick Paul Taylor
Mar 16, 2018 6:52am
EuroBiotech: More Articles of Note
Jul 13, 2017 6:15am
Serono spinout raises €29M for phase 2 Parkinson’s trials
Feb 7, 2017 5:05am
Serono spinout plots path forward for Parkinson’s drug
Sep 19, 2016 9:19am